PDL BioPharma Inc. (PDLI) announced that it has entered into a non-exclusive license agreement with Eli Lilly and Co (LLY) under PDL's Queen et al patents with respect to teplizumab, as well as other potential next generation anti-CD3 molecules.
Teplizumab is currently being studied by Lilly and its partner MacroGenics for the treatment of individuals with newly-diagnosed type 1 diabetes mellitus.
Lilly currently holds a license to the Queen et al patents with respect to solanezumab.
For comments and feedback contact: editorial@rttnews.com
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.